Related references
Note: Only part of the references are listed.Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators
Jacqueline Spayne et al.
BMJ OPEN (2021)
Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials
Joseph E. Tota et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial
Mojgan Karimi-Zarchi et al.
BMC PUBLIC HEALTH (2020)
Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study
Kate T. Simms et al.
LANCET PUBLIC HEALTH (2020)
Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination
Masayuki Sekine et al.
VACCINES (2020)
A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
Tsetsegsaihan Batmunkh et al.
VACCINE (2020)
HPV Vaccination and the Risk of Invasive Cervical Cancer
Jiayao Lei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-TypeSpecific Effectiveness and Evidence of Cross-Protection
Risa Kudo et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
HPV vaccination in Japan: what is happening in Japan?
Sayaka Ikeda et al.
EXPERT REVIEW OF VACCINES (2019)
Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study
Tim Palmer et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
Johannes A. Bogaards et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
The projected timeframe until cervical cancer elimination in Australia: a modelling study
Michaela T. Hall et al.
LANCET PUBLIC HEALTH (2019)
Vaccination protects against invasive HPV-associated cancers
Tapio Luostarinen et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Effectiveness of HPV vaccination against high grade cervical lesions in Japan
Ryo Konno et al.
VACCINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations
VACCINE (2017)
Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era
Vicki B. Benard et al.
JAMA ONCOLOGY (2017)
Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis
Gina S. Ogilvie et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
HPV vaccine cross-protection: Highlights on additional clinical benefit
Rosa De Vincenzo et al.
GYNECOLOGIC ONCOLOGY (2013)
Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?
Woo Dae Kang et al.
GYNECOLOGIC ONCOLOGY (2013)
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
Talia Malagon et al.
LANCET INFECTIOUS DISEASES (2012)
Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer
Mamiko Onuki et al.
CANCER SCIENCE (2009)
HPV type-specific risks of high-grade CIN during 4 years of follow-up:: A population-based prospective study
P. Naucler et al.
BRITISH JOURNAL OF CANCER (2007)
Human papillomavirus and cervical cancer
EM Burd
CLINICAL MICROBIOLOGY REVIEWS (2003)